title: Strontium ranelate: an effective solution for diverse fracture risks.
abstract: Osteoporosis is listed by the WHO among the ten most frequent and socio-economically important, chronic diseases of mankind. The term osteoporosis however comprises a number of different pathophysiological conditions and clinical situations of weakened bones with increased risk of fragility fractures. A modern anti-osteoporotic drug should provide qualified study results proving therapeutic efficacy over this broad range of daily clinical appearances of osteoporosis. The decision for treatment in the individual patients depends no longer only on bone mineral density. Today, the major criterion for decision making is the prospective 10-year risk for fractures. Since this risk is calculated on the basis of age, sex, bone mineral density, prevalent fractures, and a number of other contributing risk factors (Kanis et al., Osteoporos Int 12:989-995, 2001; Kanis et al., Osteoporos Int 19:385-397, 2008), it seems to be of interest to have a look whether the fracture-reducing potency of a drug is influenced by these risk factors. The purpose of this review is to analyze whether the fracture-reducing efficacy of strontium ranelate in patients with osteoporosis can be achieved independently of sex, etiology of osteoporosis, and the major diagnostically relevant risk factors.
authors.affiliation: General Internal Medicine and West-German Osteoporosis Center (WOC), Klinikum Leverkusen, D-51375, Leverkusen, Germany. ringe@klinikum-lev.de
authors.forename: J D
authors.initials: JD
authors.lastname: Ringe
mesh_terms: D015992:Body Mass Index; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D020022:Genetic Predisposition to Disease; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
references.citation: J Bone Miner Res. 2006 Apr;21(4):536-42
references.pmid: 16598373
references.citation: Osteoporos Int. 2007 Oct;18(10):1319-28
references.pmid: 17566815
references.citation: Am J Med. 1999 Mar;106(3):311-4
references.pmid: 10190380
references.citation: Lancet. 2006 Jun 17;367(9527):2010-8
references.pmid: 16782492
references.citation: Rheumatol Int. 2010 May;30(7):863-9
references.pmid: 20035331
references.citation: J Bone Miner Res. 2006 Jan;21(1):124-31
references.pmid: 16355281
references.citation: J Bone Miner Res. 2002 Apr;17(4):716-24
references.pmid: 11918229
references.citation: Ann Rheum Dis. 2008 Mar;67(3):335-9
references.pmid: 17965119
references.citation: J Bone Miner Res. 2000 Dec;15(12):2504-12
references.pmid: 11127216
references.citation: J Clin Endocrinol Metab. 2006 Oct;91(10):3908-15
references.pmid: 16849417
references.citation: Arzneimittelforschung. 2010;60(5):267-72
references.pmid: 20533764
references.citation: Calcif Tissue Int. 2001 Oct;69(4):229-34
references.pmid: 11730257
references.citation: Osteoporos Int. 2008 Apr;19(4):399-428
references.pmid: 18266020
references.citation: N Engl J Med. 2004 Jan 29;350(5):459-68
references.pmid: 14749454
references.citation: Bone. 1989;10(6):415-9
references.pmid: 2624821
references.citation: Am J Epidemiol. 1993 Aug 1;138(3):160-9
references.pmid: 8356959
references.citation: N Engl J Med. 2007 Nov 15;357(20):2028-39
references.pmid: 18003959
references.citation: J Bone Miner Res. 2005 Mar;20(3):529-35
references.pmid: 15746999
references.citation: BMJ. 1997 Oct 4;315(7112):841-6
references.pmid: 9353503
references.citation: BMJ. 1994 Sep 17;309(6956):691-5
references.pmid: 7950520
references.citation: J Clin Endocrinol Metab. 2002 Jun;87(6):2460-6
references.pmid: 12050200
references.citation: J Clin Endocrinol Metab. 2005 May;90(5):2816-22
references.pmid: 15728210
references.citation: Bone. 2008 Jan;42(1):129-38
references.pmid: 17945546
references.citation: J Bone Miner Res. 1996 Feb;11(2):293-7
references.pmid: 8822354
references.citation: Eur J Epidemiol. 2000 Mar;16(3):223-9
references.pmid: 10870936
references.citation: N Engl J Med. 2008 Apr 3;358(14):1474-82
references.pmid: 18385499
references.citation: Osteoporos Int. 2007 Apr;18(4):495-503
references.pmid: 17253119
references.citation: Osteoporos Int. 2008 Sep;19(9):1247-50
references.pmid: 18604578
references.citation: Endocrinol Metab Clin North Am. 2007 Jun;36(2):399-419
references.pmid: 17543726
references.citation: Clin Rheumatol. 2007 Apr;26(4):474-84
references.pmid: 17122953
references.citation: J Bone Miner Res. 1994 Jun;9(6):761-9
references.pmid: 8079652
references.citation: J Bone Miner Res. 2000 Jun;15(6):993-1000
references.pmid: 10841167
references.citation: J Bone Miner Res. 1994 Nov;9(11):1671-8
references.pmid: 7863817
references.citation: J Bone Miner Res. 1999 Sep;14(9):1622-7
references.pmid: 10469292